Product Datasheet

Cagrilintide

Catalog No. **BP-01126** · CAS **1415456-99-3** · Form **free base** · Physical state **solid** · Color **White to off-white** · Version **1.0** · Revision **2026-11-13**

FOR RESEARCH USE ONLY. NOT FOR HUMAN OR VETERINARY USE.

Target	Research area
CGRP Receptor	**Metabolic Disease**

Molecular formula	$C_{194}H_{312}N_{54}O_{59}S_2$
Molecular weight	**4409.0090** (free base)

SEQUENCE

{Eicosanedioicacid-γ-Glu}-Lys-Cys-Asn-Thr-Ala-Thr-Cys-Ala-Thr-Gln-Arg-Leu-Ala-Glu-Phe-Leu-Arg-His-Ser-Ser-Asn-Asn-Phe-Gly-Pro-Ile-Leu-Pro-Pro-Thr-Asn-Val-Gly-Ser-Asn-Thr-Pro-NH2(Disulfidebridge:Cys3-Cys8)

DESCRIPTION

Cagrilintide is an investigational novel long-acting acylated amylin analogue, acts as nonselective amylin receptors (AMYR) and calcitonin G protein-coupled receptor (CTR) agonist. Cagrilintide induces significant weight loss and reduces food intake. Cagrilintide has the potential for the research of obesity].

BIOLOGICAL ACTIVITY

In Vivo

Cagrilintide (compound 23) (0.1, 1, 3, 10, 30 nmol/kg; s.c.) reduces food intake in the rat[2].

Cagrilintide (10 nmol/kg; i.v. or s.c.) shows good pharmacokinetic parameters[2].

SOLUBILITY

soluble in H2O

REFERENCES

[1]. Fletcher MM, et al. AM833 Is a Novel Agonist of Calcitonin Family G Protein-Coupled Receptors: Pharmacological Comparison with Six Selective and Nonselective Agonists. J Pharmacol Exp Ther. 2021 Jun;377(3):417-440.

[2]. Kruse T, et al. Development of Cagrilintide, a Long-Acting Amylin Analogue. J Med Chem. 2021 Aug 12;64(15):11183-11194.

[3]. Dehestani B, et al. Amylin as a Future Obesity Treatment. J Obes Metab Syndr. 2021 Dec 30;30(4):320-325.

Lot CoA and SDS are separate documents.